vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and UNITED STATES ANTIMONY CORP (UAMY). Click either name above to swap in a different company.
Journey Medical Corp is the larger business by last-quarter revenue ($16.1M vs $13.0M, roughly 1.2× UNITED STATES ANTIMONY CORP). UNITED STATES ANTIMONY CORP runs the higher net margin — -2.2% vs -7.8%, a 5.6% gap on every dollar of revenue. On growth, UNITED STATES ANTIMONY CORP posted the faster year-over-year revenue change (131.4% vs 27.3%). Over the past eight quarters, UNITED STATES ANTIMONY CORP's revenue compounded faster (106.0% CAGR vs 11.0%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
United States Antimony Corp is a natural resources firm focused on exploring, mining, processing, and selling antimony, silver, and gold products. It runs production facilities in the U.S. and Mexico, serving global industrial clients in flame retardant, battery alloy, and specialty chemical manufacturing sectors.
DERM vs UAMY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $13.0M |
| Net Profit | $-1.2M | $-286.9K |
| Gross Margin | — | 20.3% |
| Operating Margin | -2.8% | -30.1% |
| Net Margin | -7.8% | -2.2% |
| Revenue YoY | 27.3% | 131.4% |
| Net Profit YoY | -182.0% | 67.5% |
| EPS (diluted) | $-0.04 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $13.0M | ||
| Q3 25 | $17.0M | $8.7M | ||
| Q2 25 | $15.0M | $10.5M | ||
| Q1 25 | $13.1M | $7.0M | ||
| Q4 24 | $12.6M | $5.6M | ||
| Q3 24 | $14.6M | $2.6M | ||
| Q2 24 | $14.9M | $3.7M | ||
| Q1 24 | $13.0M | $3.1M |
| Q4 25 | $-1.2M | $-286.9K | ||
| Q3 25 | $-2.3M | $-4.8M | ||
| Q2 25 | $-3.8M | $181.6K | ||
| Q1 25 | $-4.1M | $546.5K | ||
| Q4 24 | $1.5M | $-882.9K | ||
| Q3 24 | $-2.4M | $-727.5K | ||
| Q2 24 | $-3.4M | $202.8K | ||
| Q1 24 | $-10.4M | $-322.8K |
| Q4 25 | — | 20.3% | ||
| Q3 25 | — | 23.1% | ||
| Q2 25 | — | 27.0% | ||
| Q1 25 | — | 33.9% | ||
| Q4 24 | 82.3% | 21.4% | ||
| Q3 24 | 63.9% | 16.5% | ||
| Q2 24 | 56.0% | 34.1% | ||
| Q1 24 | 47.7% | 19.2% |
| Q4 25 | -2.8% | -30.1% | ||
| Q3 25 | -9.0% | -56.5% | ||
| Q2 25 | -19.2% | 0.2% | ||
| Q1 25 | -25.3% | 5.1% | ||
| Q4 24 | 17.7% | -19.3% | ||
| Q3 24 | -19.8% | -34.6% | ||
| Q2 24 | -19.7% | 1.5% | ||
| Q1 24 | -77.4% | -15.3% |
| Q4 25 | -7.8% | -2.2% | ||
| Q3 25 | -13.6% | -54.9% | ||
| Q2 25 | -25.3% | 1.7% | ||
| Q1 25 | -31.0% | 7.8% | ||
| Q4 24 | 12.1% | -15.7% | ||
| Q3 24 | -16.3% | -28.3% | ||
| Q2 24 | -22.6% | 5.5% | ||
| Q1 24 | -80.1% | -10.5% |
| Q4 25 | $-0.04 | $-0.01 | ||
| Q3 25 | $-0.09 | $-0.04 | ||
| Q2 25 | $-0.16 | $0.01 | ||
| Q1 25 | $-0.18 | $0.00 | ||
| Q4 24 | $0.10 | $-108943126.01 | ||
| Q3 24 | $-0.12 | $-0.01 | ||
| Q2 24 | $-0.17 | $108943126.00 | ||
| Q1 24 | $-0.53 | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $30.5M |
| Total DebtLower is stronger | $25.3M | $195.4K |
| Stockholders' EquityBook value | $31.9M | $141.0M |
| Total Assets | $94.6M | $153.9M |
| Debt / EquityLower = less leverage | 0.79× | 0.00× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $30.5M | ||
| Q3 25 | $24.9M | — | ||
| Q2 25 | $20.3M | — | ||
| Q1 25 | $21.1M | — | ||
| Q4 24 | $20.3M | $18.2M | ||
| Q3 24 | $22.5M | $13.0M | ||
| Q2 24 | $23.9M | $12.4M | ||
| Q1 24 | $24.1M | $11.9M |
| Q4 25 | $25.3M | $195.4K | ||
| Q3 25 | $25.2M | $93.2K | ||
| Q2 25 | $25.1M | $127.5K | ||
| Q1 25 | $25.0M | $161.6K | ||
| Q4 24 | $24.9M | $327.7K | ||
| Q3 24 | $19.8M | $228.9K | ||
| Q2 24 | $19.7M | $262.1K | ||
| Q1 24 | $14.7M | $0 |
| Q4 25 | $31.9M | $141.0M | ||
| Q3 25 | $25.9M | $71.8M | ||
| Q2 25 | $19.2M | $37.5M | ||
| Q1 25 | $21.5M | $32.6M | ||
| Q4 24 | $20.1M | $28.6M | ||
| Q3 24 | $10.9M | $25.1M | ||
| Q2 24 | $11.3M | $25.7M | ||
| Q1 24 | $13.0M | $25.4M |
| Q4 25 | $94.6M | $153.9M | ||
| Q3 25 | $85.2M | $79.9M | ||
| Q2 25 | $81.2M | $47.5M | ||
| Q1 25 | $85.0M | $39.5M | ||
| Q4 24 | $80.2M | $34.6M | ||
| Q3 24 | $64.0M | $29.8M | ||
| Q2 24 | $65.2M | $28.9M | ||
| Q1 24 | $66.6M | $28.0M |
| Q4 25 | 0.79× | 0.00× | ||
| Q3 25 | 0.97× | 0.00× | ||
| Q2 25 | 1.30× | 0.00× | ||
| Q1 25 | 1.16× | 0.00× | ||
| Q4 24 | 1.24× | 0.01× | ||
| Q3 24 | 1.81× | 0.01× | ||
| Q2 24 | 1.75× | 0.01× | ||
| Q1 24 | 1.13× | 0.00× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-3.5M |
| Free Cash FlowOCF − Capex | — | $-15.2M |
| FCF MarginFCF / Revenue | — | -116.7% |
| Capex IntensityCapex / Revenue | — | 90.1% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-37.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-3.5M | ||
| Q3 25 | $-2.4M | $-3.9M | ||
| Q2 25 | $-942.0K | $-627.7K | ||
| Q1 25 | $-2.8M | $-1.7M | ||
| Q4 24 | $2.2M | $1.2M | ||
| Q3 24 | $-1.2M | $411.2K | ||
| Q2 24 | $-5.2M | $565.9K | ||
| Q1 24 | $-5.0M | $65.0K |
| Q4 25 | — | $-15.2M | ||
| Q3 25 | — | $-12.5M | ||
| Q2 25 | — | $-7.2M | ||
| Q1 25 | — | $-2.6M | ||
| Q4 24 | — | $970.6K | ||
| Q3 24 | — | $338.9K | ||
| Q2 24 | — | $467.9K | ||
| Q1 24 | — | $12.3K |
| Q4 25 | — | -116.7% | ||
| Q3 25 | — | -144.1% | ||
| Q2 25 | — | -68.0% | ||
| Q1 25 | — | -37.0% | ||
| Q4 24 | — | 17.2% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 12.8% | ||
| Q1 24 | — | 0.4% |
| Q4 25 | — | 90.1% | ||
| Q3 25 | — | 99.7% | ||
| Q2 25 | — | 62.1% | ||
| Q1 25 | — | 12.3% | ||
| Q4 24 | — | 3.7% | ||
| Q3 24 | — | 2.8% | ||
| Q2 24 | — | 2.7% | ||
| Q1 24 | — | 1.7% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -3.46× | ||
| Q1 25 | — | -3.16× | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.79× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
UAMY
| Antimony | $11.8M | 90% |
| Other | $1.2M | 10% |
